A Reinforcement Learning-Based Reward Mechanism for Molecule Generation that Introduces Activity Information
暂无分享,去创建一个
[1] David S. Goodsell,et al. RCSB Protein Data Bank: biological macromolecular structures enabling research and education in fundamental biology, biomedicine, biotechnology and energy , 2018, Nucleic Acids Res..
[2] D. Diz,et al. COVID-19, ACE2, and the cardiovascular consequences , 2020, American journal of physiology. Heart and circulatory physiology.
[3] Richard J. Hall,et al. Protein-Ligand Docking against Non-Native Protein Conformers , 2008, J. Chem. Inf. Model..
[4] Thomas Blaschke,et al. Molecular de-novo design through deep reinforcement learning , 2017, Journal of Cheminformatics.
[5] Shunmugiah Karutha Pandian,et al. Quinolines-Based SARS-CoV-2 3CLpro and RdRp Inhibitors and Spike-RBD-ACE2 Inhibitor for Drug-Repurposing Against COVID-19: An in silico Analysis , 2020, Frontiers in Microbiology.
[6] Hualiang Jiang,et al. Structure of Mpro from SARS-CoV-2 and discovery of its inhibitors , 2020, Nature.
[7] Wenjie Zhu,et al. The complex structure of GRL0617 and SARS-CoV-2 PLpro reveals a hot spot for antiviral drug discovery , 2021, Nature communications.
[8] Jonas Boström,et al. Deep Reinforcement Learning for Multiparameter Optimization in de novo Drug Design , 2019, J. Chem. Inf. Model..
[9] Le Zhang,et al. Progress in molecular docking , 2019, Quantitative Biology.
[10] B. Munos. Lessons from 60 years of pharmaceutical innovation , 2009, Nature Reviews Drug Discovery.
[11] George Papadatos,et al. The ChEMBL database in 2017 , 2016, Nucleic Acids Res..
[12] Danzhi Huang,et al. Hydrogen Bonding Penalty upon Ligand Binding , 2011, PloS one.
[13] Kwok-Hung Chan,et al. Improved Molecular Diagnosis of COVID-19 by the Novel, Highly Sensitive and Specific COVID-19-RdRp/Hel Real-Time Reverse Transcription-PCR Assay Validated In Vitro and with Clinical Specimens , 2020, Journal of Clinical Microbiology.
[14] M. Cryle,et al. X-domain of peptide synthetases recruits oxygenases crucial for glycopeptide biosynthesis , 2015, Nature.
[15] Zhènglì Shí,et al. The crystal structure of COVID-19 main protease in complex with an inhibitor N3 , 2020 .
[16] Charles C. Persinger,et al. How to improve R&D productivity: the pharmaceutical industry's grand challenge , 2010, Nature Reviews Drug Discovery.
[17] Sarunas Raudys,et al. Evolution and generalization of a single neurone: I. Single-layer perceptron as seven statistical classifiers , 1998, Neural Networks.
[18] Bernardete Ribeiro,et al. Diversity oriented Deep Reinforcement Learning for targeted molecule generation , 2021, Journal of Cheminformatics.
[19] Olexandr Isayev,et al. Deep reinforcement learning for de novo drug design , 2017, Science Advances.
[20] Jacob D. Durrant,et al. Molecular dynamics simulations and drug discovery , 2011, BMC Biology.
[21] J. Takagi,et al. Engineered ACE2 receptor therapy overcomes mutational escape of SARS-CoV-2 , 2021, Nature Communications.
[22] Danushka Bollegala,et al. DeepGraphMolGen, a multi-objective, computational strategy for generating molecules with desirable properties: a graph convolution and reinforcement learning approach , 2020, Journal of Cheminformatics.
[23] A High-Throughput RNA Displacement Assay for Screening SARS-CoV-2 nsp10-nsp16 Complex toward Developing Therapeutics for COVID-19 , 2021, SLAS Discovery.
[24] John P. Overington,et al. ChEMBL: a large-scale bioactivity database for drug discovery , 2011, Nucleic Acids Res..
[25] Dong-Sheng Cao,et al. Artificial intelligence facilitates drug design in the big data era , 2019, Chemometrics and Intelligent Laboratory Systems.